I thought about making this post funny, but mental disorders are not funny, they can be sad and sometimes tragic.
Reviva Pharmaceuticals (RVPH) is scheduled to release top line data in mid-2023 from their global Phase 3 RECOVER trial of brilaroxazine in schizophrenia patients. Brilaroxazine is a serotonin/dopamine modulator in late-stage clinical development for the treatment of schizophrenia.
The company also intends to investigate brilaroxazine for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer’s disease, Parkinson’s disease psychosis, and attention deficit hyperactivity disorder (ADD/ADHD). They may initiate Phase 2a studies in bipolar disorder, major depressive disorder, and attention deficit hyperactive disorder in second half 2023, subject to the receipt of additional financing (this appears to be in work - Form 424B3 Prospectus).
If successful, commercial availability for use for schizophrenia is anticipated in early 2025.
More detailed info
Reviva Pharmaceuticals Announces Letter to Shareholders (yahoo.com)
Opening up one tomorrow with shares